Patents Examined by Maryam Monshipouri
-
Patent number: 12291554Abstract: The purpose of the present invention is to provide a modified activin A. The present invention provides activin A comprising a modified proregion.Type: GrantFiled: May 14, 2021Date of Patent: May 6, 2025Assignees: Mitsubishi Chemical Corporation, UniBio CorporationInventors: Hidehito Takayama, Risa Watanabe, Yutaka Takemoto, Hiroyuki Tanaka, Hiroshi Kawabata, Kyoji Yoshinaka
-
Patent number: 12286458Abstract: The present invention relates to the field of protein purification and relates in particular to novel proteins that bind specifically to acid alpha glucosidase (GAA). The invention further relates to fusion proteins comprising novel proteins that bind specifically to GAA. In addition, the invention relates to affinity matrices comprising the GAA binding proteins of the invention. The invention also relates to a use of these GAA binding proteins or affinity matrices for affinity purification of GAA and to methods of affinity purification of GAA using the GAA binding proteins of the invention. Further uses relate to analytical methods for the determination of GAA in liquids.Type: GrantFiled: December 17, 2020Date of Patent: April 29, 2025Assignee: Navigo Proteins GmbHInventors: Erik Fiedler, Mathias Kahl, Jonathan Lotze, Eva Bosse-Doenecke
-
Patent number: 12269852Abstract: The present invention relates to polypeptides having trehalase activity, particularly derived from Talaromyces. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides for the production of ethanol.Type: GrantFiled: September 28, 2022Date of Patent: April 8, 2025Assignee: NOVOZYMES A/SInventors: Marc Dominique Morant, Tomoko Matsui, Kirk Matthew Schnorr, Shiro Fukuyama, Noriko Tsutsumi, Zhengfang Kang
-
Patent number: 12263207Abstract: The present invention provides engineered human alpha-galactosidase polypeptides and compositions thereof. The engineered human alpha-galactosidase polypeptides have been optimized to provide improved stability under both acidic (pH<4.5) and basic (pH>7) conditions. The invention also relates to the use of the compositions comprising the engineered human alpha-galactosidase polypeptides for therapeutic purposes.Type: GrantFiled: March 9, 2021Date of Patent: April 1, 2025Assignee: Crosswalk Therapeutics, Inc.Inventors: Nicholas J. Agard, Mathew G. Miller, Xiyun Zhang, Gjalt W. Huisman
-
Patent number: 12264346Abstract: Disclosed is a modified polypeptide having mannanase activity and a use thereof.Type: GrantFiled: July 25, 2022Date of Patent: April 1, 2025Assignee: CJ CHEILJEDANG CORPORATIONInventors: Byung-sam Son, Hyun Kug Cho, Eun Jung Choi
-
Patent number: 12258625Abstract: The technology described herein is directed to compositions, methods, and systems for measuring the interactions between RNAs and proteins.Type: GrantFiled: April 4, 2023Date of Patent: March 25, 2025Assignee: TRUSTEES OF BOSTON UNIVERSITYInventors: Daniel Cifuentes Buira, Dmitry Kretov
-
Patent number: 12257291Abstract: The present invention provides engineered human alpha-galactosidase polypeptides and compositions thereof. The engineered human alpha-galactosidase polypeptides have been optimized to provide improved stability under both acidic (pH<4.5) and basic (pH>7) conditions. The invention also relates to the use of the compositions comprising the engineered human alpha-galactosidase polypeptides for therapeutic purposes.Type: GrantFiled: May 6, 2024Date of Patent: March 25, 2025Assignee: Crosswalk Therapeutics, Inc.Inventors: Nicholas J. Agard, Mathew G. Miller, Xiyun Zhang, Gjalt W. Huisman
-
Patent number: 12227784Abstract: The present invention relates to a process for improving the nutritional quality of distillers dried grains (DGS) or distillers dried grains with solubles (DDGS) produced as a co-product of a fermentation product production process, processes for producing fermentation products, as well as enzyme blends used in the processes.Type: GrantFiled: September 12, 2018Date of Patent: February 18, 2025Assignee: Novozymes A/SInventors: Jesper Frickmann, Kendra Stallings, Dan Pettersson, Mads Brøgger Pedersen, Harold Cale Smith
-
Patent number: 12221639Abstract: The present invention provides a novel allulose epimerase variant in which an amino acid residue present at a specific position of an amino acid sequence of wild-type D-allulose 3-epimerase derived from Flavonifractor plautii is substituted with another amino acid residue, and various uses thereof. The novel allulose epimerase variant according to the present invention has a higher conversion activity of fructose to allulose than that of the wild-type D-allulose 3-epimerase derived from Flavonifractor plautii or a D-allulose epimerase variant W29K/G216S/M234I, and has excellent thermal stability especially under high temperature conditions of 60° C. or higher, thereby preventing contamination during an industrial-scale enzymatic conversion reaction for the mass production of allulose, shortening the production time, and reducing the production costs.Type: GrantFiled: November 22, 2021Date of Patent: February 11, 2025Assignee: DAESANG CORPORATIONInventors: Ji Ha Lee, Tae Gyun Kim, Baek Joong Kim, Da Han Jung, Seung Woo Cho, Hak Jun Kim
-
Patent number: 12209139Abstract: Expression vectors and methods of protein purification, which allow for selection of full length protein over truncated forms of the protein being purified, are disclosed. The methods express a target protein as a three domain fusion, represented by formula I:A-[Li]-B-[L2]-C, where A is a first purification tag domain, C is the second purification tag domain and B is the target protein domain. A, B and C are preferably covalently linked by linkers, L1 and L2 may be optional. The purification tags at the N and C termini are different. The purification tags at the N and C termini are different. Expression vectors including nucleic acid sequences which encode the fusion protein represented by formula I are also disclosed. The vectors are used with host expression systems such as insect, yeast, or mammalian cells to express the target protein, which is subsequently purified as a function of the different affinity tags.Type: GrantFiled: August 20, 2021Date of Patent: January 28, 2025Assignee: KING ABDULLAH UNIVERSITY OF SCIENCE AND TECHNOLOGYInventors: Samir M. Hamdan, Vlad-Stefan Raducanu
-
Patent number: 12195778Abstract: The present disclosure provides, in some aspects, variant RNA polymerases, the use of which increases transcription efficiency while reducing the number of double-stranded RNA contaminates and run-on transcripts produced during an in vitro transcription reaction.Type: GrantFiled: August 11, 2023Date of Patent: January 14, 2025Assignee: ModernaTX, Inc.Inventors: Amy E. Rabideau, Athanasios Dousis, Kanchana Ravichandran, Elissa Hobert
-
Patent number: 12195707Abstract: The membrane bioreactor for simultaneous enzymatic cellulose hydrolysis and product separation is a vessel having a lower hydrolysis reaction chamber and an upper distilled water chamber separated by a semipermeable membrane attached to the top of the lower reaction chamber. The membrane is supported on a stainless steel mesh and sealed to the mesh by epoxy glue to prevent leakage. A peristaltic pump is connected to the reaction chamber and maintains a flow of distilled water through the membrane and the upper chamber, the effluent being collected in a beaker or other product collection vessel. The reaction chamber is agitated at a moderate rate by a magnetic stirrer, and the upper chamber is agitated more rigorously by a mechanical stirrer. A thermocouple and temperature controller and a buffer solution, respectively, maintain temperature and pH in the reaction chamber optimal for enzymatic hydrolysis of cellulose.Type: GrantFiled: October 4, 2022Date of Patent: January 14, 2025Assignee: UNITED ARAB EMIRATES UNIVERSITYInventors: Saleha Al-Mardeai, Sulaiman Al-Zuhair, Bart Van Der Bruggen, Emad Elnajjar, Boguslaw Kruczek
-
Patent number: 12195776Abstract: The present invention relates to recombinant filamentous fungal host cells producing cellulolytic enzyme compositions and methods of producing and using the compositions.Type: GrantFiled: December 10, 2021Date of Patent: January 14, 2025Assignee: Novozymes, Inc.Inventors: Jeffrey Shasky, Amanda Fischer, Suchindra Maiyuran
-
Patent number: 12188024Abstract: A transformant obtained by introducing a DNA of (a1), (a2), or (a3) below, and (b) an alcohol dehydrogenase gene, into a bacterium of the genus Hydrogenophilus, can efficiently produce isobutanol utilizing carbon dioxide as a sole carbon source. (a1) DNA which consists of a base sequence of SEQ ID NO: 1; (a2) DNA which consists of a base sequence having 90% or more identity with SEQ ID NO: 1, the DNA encoding a polypeptide having 2-keto-acid decarboxylase activity; (a3) DNA which hybridizes with a DNA consisting of a base sequence complementary to SEQ ID NO: 1 under stringent conditions, and which encodes a polypeptide having 2-keto-acid decarboxylase activity.Type: GrantFiled: May 11, 2023Date of Patent: January 7, 2025Assignees: Utilization of Carbon Dioxide Institute Co., Ltd., The University of TokyoInventors: Hideaki Yukawa, Naoto Ohtani, Masaharu Ishii
-
Patent number: 12188025Abstract: A transformant obtained by introducing a DNA of (a1), (a2), or (a3) below, and (b) an alcohol dehydrogenase gene, into a bacterium of the genus Hydrogenophilus, can efficiently produce isobutanol utilizing carbon dioxide as a sole carbon source. (a1) DNA which consists of a base sequence of SEQ ID NO: 1; (a2) DNA which consists of a base sequence having 90% or more identity with SEQ ID NO: 1, the DNA encoding a polypeptide having 2-keto-acid decarboxylase activity; (a3) DNA which hybridizes with a DNA consisting of a base sequence complementary to SEQ ID NO: 1 under stringent conditions, and which encodes a polypeptide having 2-keto-acid decarboxylase activity.Type: GrantFiled: May 11, 2023Date of Patent: January 7, 2025Assignees: Utilization of Carbon Dioxide Institute Co., Ltd., The University of TokyoInventors: Hideaki Yukawa, Naoto Ohtani, Masaharu Ishii
-
Patent number: 12187769Abstract: The present invention relates to a cell comprising a chimeric antigen receptor (CAR) and a constitutively active or inducible Signal Transducer and Activator of Transcription (STAT) molecule.Type: GrantFiled: May 24, 2023Date of Patent: January 7, 2025Assignee: AUTOLUS LIMITEDInventors: Martin Pulé, Shaun Cordoba, Simon Thomas, Shimobi Onuoha, Matteo Righi
-
Patent number: 12173340Abstract: Disclosed is an expression vector comprising a polynucleotide encoding for a glutamine synthetase with reduced activity compared to a wild type glutamine synthetase. Also disclosed are host cells, methods for preparing stable cell line, methods of producing polypeptide of interest, and kits thereof.Type: GrantFiled: November 16, 2017Date of Patent: December 24, 2024Assignee: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCHInventors: Pao Chun Lin, Zhiwei Song
-
Patent number: 12173343Abstract: Embodiments herein relate to methods, systems and kits for engineering antimicrobial peptides such as bacteriocins, for example to have a desired range of activity in a desired range of culture conditions. The antimicrobial peptides may be engineered to have a particular activity for a particular culture, environmental conditions or a range of conditions. Some embodiments include screening an antimicrobial peptides or several candidate antimicrobial peptides for a desired activity. Some embodiments include an iterative process for engineering antimicrobial peptides such as bacteriocins. In some embodiments, the process is performed by automated machine learning.Type: GrantFiled: June 5, 2019Date of Patent: December 24, 2024Assignee: Syngulon SAInventor: Philippe Gabant
-
Patent number: 12157762Abstract: Disclosed are nucleic acids and polypeptides which provide the co-expression of interleukin (IL)-21 and IL-15 by a host cell, each interleukin being bound to the cell membrane by a cell membrane anchor moiety. Also disclosed are related recombinant expression vectors, host cells, populations of cells, pharmaceutical compositions, and methods of treating or preventing cancer.Type: GrantFiled: May 2, 2023Date of Patent: December 3, 2024Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Christian S. Hinrichs, Benjamin Y. Jin
-
Patent number: 12146175Abstract: A method for producing a recombinant collagen-like protein (CLP) can be performed. The method includes fermenting a host cell, accumulating the CLP in a medium to obtain a fermentation broth, separating the host cell from the fermentation broth to obtain a supernatant, and incubating the supernatant. The CLP can be purified after incubation.Type: GrantFiled: August 3, 2022Date of Patent: November 19, 2024Assignee: Evonik Operations GmbHInventors: Christian Bangert, Steffen Oßwald